TITLE

LONG-TERM ANTICOAGULANT TREATMENT IN CORONARY DISEASE

AUTHOR(S)
Royston, G. R.
PUB. DATE
March 1967
SOURCE
Angiology;Mar1967, Vol. 18 Issue 3, p133
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Patients with coronary disease (461 cases) have been treated with anticoagulants for from 6 months to over 8 years, a total of more than 1150 treatment years. The method of control of the ACT is described and the degrees of control assessed. It is emphasized that a case should be adequately anticoagulated at least 85 per cent of the time in order to render treatment effective. It is stressed that descriptions of ACT must include data of the degree of control in order that the prescribed therapy can be shown to have been carried out. The survival rate after myocardial infarction with or without previous infarction and with or without angina at 3 years and 5 years for the combined sexes was 91 per cent and 83 per cent respectively. The corresponding figures for males only are 92 per cent and 84 per cent. In terms of man-months, the male mortality was 0.33 per 100 man-months. The survival rate in angina alone was 93 per cent and 86 per cent at 3 years and 5 years, or a mortality rate of 0.26 per 100 man-months for males alone. Total male relapses, including fatal ones, were 0.42 per 100 man-months for myocardial infarction and 0.16 for angina only cases. Comparison with previously described series treated without anticoagulants shows diminished recurrence rate and decreased mortality in the treated series both for the angina only group and the myocardial infarction with or without angina group. The improved prognosis in males on ACT relates to both the under and over age 55 groups, particularly the former, and extends for at least 5 years. The numbers were insufficient for analysis of the females separately. Long-term anticoagulant therapy is indicated in males with angina or following infarction irrespective of age provided they are otherwise fit to lead a normal life for their age. The limit to the duration of effective long-term ACT is not yet apparent. Further studies on ACT in coronary disease should concentrate on the degree of control therapy achieved.
ACCESSION #
16437412

 

Related Articles

  • Bivalirudin reduced adverse clinical events during primary PCI. Jacob, Harry S. // Hem/Onc Today;6/25/2008, Vol. 9 Issue 11, p27 

    The article reports that patients undergoing percutaneous coronary intervention (PCI) for ST-segment elevation mycardial infarction (MI) may benefit from bivalirudin alone, compared with heparin plus glycoprotein IIb/IIIa inhibitors, according to researchers. The researchers from various sites...

  • Antithrombotic Therapy. Duvall, W. L. // Current Molecular Medicine;Aug2006, Vol. 6 Issue 5, p603 

    Coronary heart disease is the leading cause of death in the US and the industrialized world. Ever since DeWood in 1980 demonstrated that a thrombus was the primary event leading to acute myocardial infarction and that they may subsequently lyse, the mainstay of therapy for the past 25 years has...

  • Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. P.-G. Chassot; A. Delabays; D. R. Spahn // BJA: The British Journal of Anaesthesia;Aug2007, Vol. 99 Issue 3, p316 

    Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal is much higher than that of surgical bleeding if they are continued. In secondary prevention, aspirin is a lifelong therapy and should never be stopped. Clopidogrel is regarded as mandatory until...

  • Spotlight on Enoxaparin in ST-Segment Elevation Myocardial Infarction. Carter, Natalie J.; McCormack, Paul L.; Plosker, Greg L. // BioDrugs;2008, Vol. 22 Issue 5, p343 

    Enoxaparin (enoxaparin sodium; Lovenox) is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention. It binds to and...

  • Facilitated Percutaneous Coronary Intervention: Pharmacological and Mechanical Synergy in Reperfusion for ST-Elevation Myocardial Infarction. Part 2. Choo, Joseph; Young, John; Kereiakes, Dean // Current Medical Literature: Interventional Cardiology Monitor;2004, Vol. 11 Issue 2, p29 

    Discusses the use of fibrinolytic drugs with percutaneous coronary intervention (PCI). Steps in minimizing bleeding complications with improved vascular access care and anticoagulation monitoring; Benefit attributable to abciximab in conjunction with PCI for STEMI.

  • Novel Antithrombotic Agents: Indirect Synthetic Inhibitors of Factor Xa and Direct Thrombin Inhibitors. Evidences from Clinical Studies. Leone, Giuseppe; Rossi, Elena; Leone, Antonio Maria; Stefano, Valerio De // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Oct2004, Vol. 2 Issue 4, p311 

    The optimal drugs employed in the antithrombotic treatment and prophylaxis have ideally been suggested to have high efficacy and safety and to be easy to use as regards the administration route and the fashion of monitoring the anticoagulant effect. A number of agents are under development in...

  • Blood Thinners and Your Brain.  // Mind, Mood & Memory;Nov2014, Vol. 10 Issue 11, p6 

    The article focuses on the proper use of blood thinners or antithrombotic medications. Topics discussed include the use of antithrombotics for preventing heart attacks and brain-damaging strokes and the emergence of a new generation of oral anticoagulants. Also mentioned are the risk of bleeding...

  • Risk of death in abrupt clopidogrel cessation. Praities, Nigel // Pulse;2/13/2008, Vol. 68 Issue 5, p10 

    The article focuses on the issue concerning the adverse effect of abrupt cessation in using clopidogrel, a potent oral antiplatelet agent used in treating coronary artery disease. It reports that patients who are abruptly taken off clopidogrel are vulnerable to risk of a myocardial infarction or...

  • Acute inferior myocardial infarction in a patient with a prosthetic aortic valve and high international normalized ratio. Atas, Halil; Sari, Ibrahim; Delil, Kenan; Ileri, Cigdem; Samadov, Fuad // Advances in Interventional Cardiology;2014, Vol. 10 Issue 1, p63 

    ST elevation acute myocardial infarction in patients with a mechanical prosthetic valve is rare and usually due to inadequate anticoagulation. We present a case of acute inferior myocardial infarction in a patient with a prosthetic aortic valve and high international normalized ratio, which has...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics